Physiologically based pharmacokinetic modeling

Veterinary Toxicology

Volumn , Issue , 2007, Pages 42-50

  Van Der Merwe, Deon ^a   Buur, Jennifer L ^b   Riviere, Jim E ^b  

^a KANSAS STATE UNIVERSITY   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84864050722     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012370467-2/50100-0     Document Type: Chapter

References (26)

1. Andersen ME, Green T, Frederick CB, Bogdanffy MS Physiologically based pharmacokinetic (PBPK) models for nasal tissue dosimetry of organic esters, assessing the state-of-knowledge and risk assessment applica. Regul Toxicol Pharm 2002, 36:234-245.
2. Andersen ME, Lutz RW, Liao KH, Lutz WK Dose-incidence modeling, consequences of linking quantal measures of response to depletion of critical tissue targets. Toxicol Sci 2006, 89:331-337.
3. Audoly S, Bellu G, D'Angio L, Saccomani MP, Cobelli C Global identifiability of nonlinear models of biological systems. IEEE Trans Biomed Eng 2001, 48:55-65.
4. Brocklebank JR, Namdri R, Law FC An oxytetracycline residue depletion study to assess the physiologically based phar-macokinetic (PBPK) model in farmed Atlantic salmon. Can Vet J 1997, 38:645-646.
5. Buur JL, Baynes RE, Craigmill AL, Riviere JE Development of a physiologic-based pharmacokinetic model for estimating sul-famethazine concentrations in swine and application to prediction of violative res. Am J Vet Res 2005, 66:1686-1693.
6. Buur J, Baynes R, Smith G, Riviere JE The use of probabilistic modeling within a physiological based pharmacokinetic model to predict drug residue withdrawal times in edible tissue, sulfamet-hazin. Antimicrob Agents Chemother 2006, 50:2344-2351.
7. Clewell HJ, Gentry PR, Kester JE, Andersen ME Evaluation of physiologically based pharmacokinetic models in risk assessment, an example with perchloroethylene. Crit Rev Toxicol 2005, 35:413-433.
8. Colburn WA Physiologic pharmacokinetic modeling. J Clin Pharmacol 1988, 28:673-677.
9. Craigmill AL A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. J Vet Pharmacol Ther 2003, 26:55-63.
10. Evans MV, Andersen ME Sensitivity analysis of a physiological model for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) , assessing the impact of specific model parameters on sequestrat. Toxicol Sci 2000, 54:71-80.
11. Fisher JW, Whittaker TA, Taylor DH, Clewell HJ, Andersen ME Physiologically based pharmacokinetic modeling of the lactating rat and nursing pup, a multiroute exposure model for trichloroethylene and its metabolite, tri. Toxicol Appl Pharmacol 1990, 102:497-513.
12. Frederick CB, Lomax LG, Black KA, Finch L, Scribner HE, Kimbell JS, Morgan KT, Subramaniam RP, Morris JB Use of a hybrid computational fluid dynamics and physiologically based inhala-tion model for interspecies dosimetry comparisons of ester vapors. Toxicol Appl Pharmacol 2002, 183:23-40.
13. Gabrielsson JL Utilization of physiologically based models in extrapolating pharmacokinetic data among species. Fundam Appl Toxicol 1991, 16:230-232.
14. Gabrielsson JL, Paalzow LK, Nordstrom L A physiologically based pharmacokinetic model for theophylline disposition in the pregnant and nonpregnant rat. J Pharmacokinet Biopharm 1984, 12:149-165.
15. Gentry PR, Covington TR, Clewell HJ, Anderson ME Application of a physiologically based pharmacokinetic model for reference dose and reference concentration estimation for ace-tone. J. Toxicol Environ Health A 2003, 66:2209-2225.
16. Krishnan K, Andersen ME Physiologically based pharmacokinetic modeling in toxicology. Principles and Methods of Toxicology 2001, 193-241. Taylor & Francis, Philadelphia. A.W. Hayes (Ed.).
17. Krishnan K, Gargas ML, Fennell TR, Andersen ME A physio-logically based description of ethylene oxide dosimetry in the rat. Toxicol Ind Health 1992, 8:121-140.
18. McCarley KD, Bunge AL Pharmacokinetic models of dermal absorption. J. Pharm Sci 2001, 90:1699-1719.
19. Ritschel WA, Banerjee PS Physiological pharmacokinetic mod-els, principles, applications, limitations and outlook. Methods Find Exp Clin Pharmacol 1986, 8:603-614.
20. Riviere JE Comparative Pharmacokinetics, Principles, Techniques, and Applications 1999, Iowa State University Press, Ames.
21. Sato A, Endoh K, Kaneko T, Johanson G A simulation study of physiological factors affecting pharmacokinetic behaviour of organic solvent vapours. Br J Ind Med 1991, 48:342-347.
22. Sheiner LB Analysis of pharmacokinetic data using para-metric models. II. Point estimates of an individual's parameters. J Pharmacokinet Biopharm 1985, 13:515-540.
23. Simmons JE, Evans MV, Boyes WK Moving from external exposure concentration to internal dose, duration extrapolation based on physiologically based pharmacokinetic derived esti-mates of inte. J Toxicol Environ Health A 2005, 68:927-950.
24. Sweeney LM, Tyler TR, Kirman CR, Corley RA, Reitz RH, Paustenbach DJ, Holson JF, Whorton MD, Thompson KM, Gargas ML Proposed occupational exposure limits for select ethylene glycol ethers using PBPK models and Monte Carlo simulations. Toxicol Sci 2001, 62:124-139.
25. Thomas RS, Lytle WE, Keefe TJ, Constan AA, Yang RS Incorporating Monte Carlo simulation into physiologically based pharmacokinetic models using advanced continuous simulation language (ACSL) , a computational. Fundam Appl Toxicol 1996, 31:19-28.
26. Van der Merwe D, Brooks JD, Gehring R, Baynes RE, Monteiro-Riviere NA, Riviere JE A physiological-based pharmacoki-netic model of organophosphate dermal absorption. Toxicol Sci 2006, 89:188-204.